Anlotinib Improves Survival in Advanced NSCLC Subtypes

In patients with previously treated advanced non-small cell lung cancer (NSCLC), anlotinib increases progression-free survival in squamous cell carcinoma (SCC) and improves both overall and progression-free survival in adenocarcinoma, according to a subgroup analysis of a phase 3 trial. Treatment selection for NSCLC has become largely dependent on histological subtype. In the ALTER0303 trial, anlotinib, a multitargeted tyrosine kinase inhibitor (TKI), showed significant survival benefits among p...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.